Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2025-11-06 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement (1492 characters) notifying the availability of the audio recording of a conference call regarding the unaudited financial results for the quarter and half year ended 30th September 2025. It references the conference call and provides a link to the recording on the company's website. There is no actual financial data or transcript included in the text. According to the 'Menu vs Meal' rule, this is an announcement about a conference call recording, not the transcript itself. Therefore, it should be classified as a Regulatory Filing (RNS) since it does not fit other categories and is a general regulatory announcement.
2025-11-06 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is a press release and investor presentation announcing the unaudited financial results for the quarter and half year ended 30th September 2025. It contains detailed financial highlights, business updates, and a consolidated profit and loss statement, along with balance sheet data. The document also includes an invitation to a conference call to discuss these results. The presence of detailed financial data and analysis for a period shorter than a full fiscal year (quarter and half year) indicates this is an Interim / Quarterly Report. It is not merely an announcement or a brief summary, but a comprehensive report with substantive financial data and business commentary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2026
2025-11-05 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release and investor presentation announcing the unaudited financial results for the quarter and half year ended 30th September 2025. It contains detailed financial highlights, business updates, and a conference call invitation for discussing these results. The document includes actual financial data such as revenue, EBITDA, profit/loss, and balance sheet items, indicating it is a substantive financial report for a period shorter than a full fiscal year. The presence of detailed financial statements and analysis for Q2 and H1 FY26 aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, nor is it a full annual report or earnings release with only key highlights. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2026
2025-11-05 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 90% confidence The document is the board meeting outcome under SEBI Listing Regulations where the company “has approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half‐year ended 30th September 2025,” and directly includes the full tabular financial statements (revenue, expenses, PBT, taxes, net profit, OCI, etc.). This is a comprehensive quarterly and half‐year financial report containing substantive financial data, fitting the definition of an Interim/Quarterly Report (IR), rather than a brief earnings release (ER) or a publication announcement (RPA). H1 2026
2025-11-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which pertains to disclosure of material events or information. The content is an announcement of upcoming investor meetings, not a financial report, earnings release, or detailed presentation. It is a regulatory announcement informing the market about scheduled investor interactions. The document length is short (1779 characters), and it does not contain financial data or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-11-03 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-10-24 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.